Impact of Plant-Derived Compounds on Amyotrophic Lateral Sclerosis

Neurotox Res. 2023 Jun;41(3):288-309. doi: 10.1007/s12640-022-00632-1. Epub 2023 Feb 17.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal illness characterized by progressive motor neuron degeneration. Conventional therapies for ALS are based on treatment of symptoms, and the disease remains incurable. Molecular mechanisms are unclear, but studies have been pointing to involvement of glia, neuroinflammation, oxidative stress, and glutamate excitotoxicity as a key factor. Nowadays, we have few treatments for this disease that only delays death, but also does not stop the neurodegenerative process. These treatments are based on glutamate blockage (riluzole), tyrosine kinase inhibition (masitinib), and antioxidant activity (edaravone). In the past few years, plant-derived compounds have been studied for neurodegenerative disorder therapies based on neuroprotection and glial cell response. In this review, we describe mechanisms of action of natural compounds associated with neuroprotective effects, and the possibilities for new therapeutic strategies in ALS.

Keywords: Amyotrophic lateral sclerosis; Glial cells; Motor neurons; Natural compounds; Neuroprotection.

Publication types

  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis* / complications
  • Amyotrophic Lateral Sclerosis* / drug therapy
  • Edaravone / therapeutic use
  • Glutamic Acid
  • Humans
  • Phytochemicals / therapeutic use
  • Riluzole

Substances

  • Riluzole
  • Edaravone
  • Glutamic Acid
  • Phytochemicals